Interestingly, TP53BP2, one of the 14 genes, has been proved to activate CD4+ and CD8+ immune and negatively regulate the MAPK signaling pathway in triple-negative breast cancers (38). This evidence concerns the gene TP53BP2 and triple-negative breast carcinoma.